| Literature DB >> 35025755 |
Patrick Sean Sullivan1, Rob Stephenson2, Sabina Hirshfield3, Cyra Christina Mehta4,5, Ryan Zahn1, Jose A Bauermeister6, Keith Horvath7, Mary Ann Chiasson8,9, Deborah Gelaude10, Shelby Mullin1, Martin J Downing11, Evelyn Jolene Olansky10,12, Sarah Wiatrek1, Erin Q Rogers1,2, Eli Rosenberg13, Aaron J Siegler1, Gordon Mansergh10.
Abstract
BACKGROUND: Gay, bisexual, and other men who have sex with men (GBMSM) face the highest burden of HIV in the United States, and there is a paucity of efficacious mobile health (mHealth) HIV prevention and care interventions tailored specifically for GBMSM. We tested a mobile app combining prevention messages and access to core prevention services for GBMSM.Entities:
Keywords: HIV; HIV prevention; MSM; PrEP; STI; United States; app; behavior; bisexual; efficacy; gay; mHealth; men who have sex with men; prevention; randomized clinical trial; sexuality; testing; tool; video
Mesh:
Year: 2022 PMID: 35025755 PMCID: PMC8851328 DOI: 10.2196/34574
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Eligibility criteria for a randomized controlled trial of the Mobile Messaging for Men intervention in Atlanta, Detroit, and New York City (2018-2019).
| Criterion | Eligible level |
| Age (years) |
≥18 |
| Sex at birth |
Assigned as male |
| Current gender identity |
Male |
| Sexual risk behaviors |
Reports anal intercourse with a male partner in the past 12 months |
| City of residence |
Resident of Atlanta, Detroit, or New York City |
| Other eligibility criteria |
Plans to stay in the city area for the next 9 months Owns and uses an Android or iOS smartphone Is able to read and understand English without assistance |
Outcomes and measures used in the evaluation of Mobile Messaging for Men, a mobile health intervention to promote HIV prevention and care behaviors among GBMSMa in Atlanta, Detroit, and New York City (2018-2019).
| Behavior | Group assessed | Definition |
| STIb testing |
All GBMSM | STI testc in the 3 months before the survey |
| HIV testing |
Low-risk HIV-negative GBMSM High-risk HIV-negative GBMSM | Self-reportedd HIV test in the 3 months before the survey |
| Current PrEPe use |
Low-risk HIV-negative GBMSM High-risk HIV-negative GBMSM | Self-reportedd being on PrEP as of the day of the survey |
| PrEP adherence |
All low- and high-risk HIV-negative GBMSM reporting PrEP use | Self-reportedd taking at least 25/30 daily pills in the prior 30 days |
| Current ARTf use |
All LWHg GBMSM | Self-reportedd being on ART as of the day of the survey |
| ART adherence |
All LWH GBMSM on ART | Self-reportedd taking ART, as prescribed, on ≥25 of the past 30 days |
| Anal sex not protected by PrEP or condoms |
Low-risk HIV-negative GBMSM High-risk HIV-negative GBMSM | Self-reported anal sex with a main or casual partner when the participant was not on PrEP AND the insertive partner did not use a condom from start to finishd |
| Anal sex not protected by PrEP or condoms |
LWH GBMSM | Self-reported anal sex with a main or casual partner when the insertive partner did not use a condom from start to finishd |
aGBMSM: gay, bisexual, and other men who have sex with men.
bSTI: sexually transmitted infection.
cIncludes Mobile Messaging for Men care kit orders with results.
dSelf-report measures were previously validated as part of the American Men’s Internet Survey [32].
ePrEP: preexposure prophylaxis.
fART: antiretroviral therapy.
gLWH: living with HIV.
Sociodemographic and baseline behavioral characteristics of MSMa in the Mobile Messaging for Men study sample (2018-2019).
| Characteristic | Overall (N=1220) | High-riskb HIV-negative (n=427) | Low-riskc HIV-negative (n=410) | HIV-positive (n=383) | ||||||
|
| n (%) | n (%) | n (%) | n (%) | ||||||
|
| ||||||||||
|
| MSM of color | 709 (58.11) | 205 (48.0) | .89 | 204 (49.8) | .92 | 300 (78.3) | .84 | ||
|
| White | 510 (41.80) | 222 (52.0) | —f | 206 (50.2) | — | 82 (21.4) | — | ||
|
| ||||||||||
|
| 18-29 | 448 (36.72) | 210 (49.2) | .13 | 180 (43.9) | .89 | 58 (15.1) | .58 | ||
|
| ≥30 | 772 (63.28) | 217 (50.8) | — | 230 (56.1) | — | 325 (84.9) | — | ||
|
| ||||||||||
|
| ≤High school diploma/General Education Development (GED) test | 176 (14.42) | 54 (12.6) | .96 | 31 (7.6) | .46 | 91 (23.8) | .76 | ||
|
| Some post–high school education | 387 (31.72) | 128 (29.9) | — | 98 (23.9) | — | 161 (42.0) | — | ||
|
| 4-year college degree | 377 (30.90) | 141 (33.0) | — | 158 (38.5) | — | 78 (20.4) | — | ||
|
| Some graduate education | 277 (22.70) | 102 (23.9) | — | 123 (30.0) | — | 52 (13.6) | — | ||
|
| ||||||||||
|
| Atlanta | 473 (38.77) | 140 (32.8) | .98 | 145 (35.4) | .99 | 188 (49.1) | .98 | ||
|
| Detroit | 333 (27.29) | 155 (36.3) | — | 121 (29.5) | — | 57 (14.9) | — | ||
|
| New York City | 414 (33.93) | 132 (30.9) | — | 144 (35.1) | — | 138 (36.0) | — | ||
|
| ||||||||||
|
| STIh testing (3 months) | — | 165 (38.4) | .18 | 254 (61.9) | .27 | 271 (71) | .09 | ||
|
| HIV testing (3 months) | — | 162 (37.9) | .40 | 259 (63.2) | .74 | — | — | ||
|
| Current PrEPi use | — | 22 (5.1) | .08 | 222 (54.1) | .21 | — | — | ||
|
| PrEP adherence (≥25/30 days)j | — | 11 of 22 (50.0) | .36 | 212 of 222 (95.5) | .99 | — | — | ||
|
| Current ARTk use | — | — | — | — | — | 368 (96.1) | .99 | ||
|
| ART adherence (≥25/30 days)j | — | — | — | — | — | 335 of 368 (91.0) | .06 | ||
|
| Unprotected anal sex (3 months)l | — | 392 (91.8) | .37 | 51 (12.4) | .73 | 98 (25.6) | .01 | ||
|
| Engagement in care (3 months)m | — | 45 (10.5) | .10 | 196 (47.8) | .42 | 251 (65.5) | .06 | ||
aMSM: men who have sex with men.
bHigh risk (condomless/PrEP-less anal sex, past 3 months).
cLow risk (no condomless/PrEP-less anal sex, past 3 months).
dP value for chi-square testing (difference between intervention and control arms).
eOne HIV-positive participant did not report race/ethnicity.
fNot applicable.
gTwo high-risk HIV-negative and one HIV-positive participants did not report education level.
hSTI: sexually transmitted infection.
iPrEP: preexposure prophylaxis.
jAmong current users.
kART: antiretroviral therapy.
lCondomless and PrEP-less anal sex for HIV-negative and condomless/detectable viral load for HIV-positive users.
mEngagement in PrEP or ART care.
Figure 1CONSORT diagram for the M-cubed randomized controlled trial among GBMSM (screening through randomization). CONSORT: Consolidated Standards of Reporting Trials; GBMSM: gay, bisexual, and other men who have sex with men; M-cubed: Mobile Messaging for Men.
Figure 2CONSORT diagram for a randomized controlled trial of the M-cubed intervention for GBMSM (randomization through analysis). CONSORT: Consolidated Standards of Reporting Trials; GBMSM: gay, bisexual, and other men who have sex with men; M-cubed: Mobile Messaging for Men.
Modeled behavioral measures at baseline, immediate posttest, and 3- and 6-month postintervention follow-up assessments for intervention efficacy of the Mobile Messaging for Men mobile app among MSMa by HIV status/risk group (N=1220).
| Behavioral | High-risk HIV-negative MSM (n=427) | Low-risk HIV-negative MSM (n=410) | HIV-positive MSM (n=383) | |||||||||
|
|
| Intervention group, M%b (95% CI) | Control group, M% (95% CI) | aORc
| Intervention group, M% (95% CI) | Control group, M% (95% CI) | aOR | Intervention group, M% (95% CI) | Control group, M% (95% CI) | aOR | ||
|
| ||||||||||||
|
| Baseline | 35 (28-43) | 41 (34-49) | —e | 58 (50-66) | 64 (55-71) | — | 76 (68-82) | 68 (59-75) | — | ||
|
| Immediate posttest | 42 (35-50) | 47 (39-55) | 1.07 | 61 (53-69) | 56 (48-65) | 1.53 | 65 (56-73) | 72 (63-79) |
| ||
|
| 3 months postintervention | 39 (31-47) | 45 (37-53) | 1.01 | 63 (54-71) | 56 (48-64) | 1.65 | 72 (63-79) | 59 (50-68) | 1.19 | ||
|
| 6 months postintervention | 37 (30-45) | 42 (34-50) | 1.06 | 57 (48-66) | 58 (49-66) | 1.22 | 71 (62-78) | 63 (54-72) | 0.96 | ||
|
| ||||||||||||
|
| Baseline | 48 (39-57) | 52 (44-60) | — | 73 (65-80) | 71 (63-78) | — | — | — | — | ||
|
| Immediate posttest | 63 (55-71) | 51 (42-59) |
| 75 (67-81) | 65 (57-73) | 1.41 | — | — | — | ||
|
| 3 months postintervention | 47 (39-55) | 52 (44-60) | 0.98 | 69 (61-77) | 66 (58-73) | 1.03 | — | — | — | ||
|
| 6 months postintervention | 53 (45-61) | 50 (42-58) | 1.34 | 68 (60-76) | 68 (59-75) | 0.90 | — | — | — | ||
|
| ||||||||||||
|
| Baseline | 3 (2-7) | 7 (4-11) | — | 55 (45-64) | 49 (39-58) | — | — | — | — | ||
|
| Immediate posttest | 9 (6-14) | 15 (11-21) | 1.26 | 52 (42-62) | 49 (39-58) | 0.89 | — | — | — | ||
|
| 3 months postintervention | 15 (10-21) | 14 (10-20) |
| 52 (42-61) | 48 (39-59) | 0.88 | — | — | — | ||
|
| 6 months postintervention | 15 (11-21) | 19 (14-26) | 1.67 | 51 (42-61) | 49 (39-58) | 0.85 | — | — | — | ||
|
| ||||||||||||
|
| Baseline | 35 (10-71) | 62 (37-82) | — | 95 (89-98) | 95 (88-98) | — | — | — | — | ||
|
| Immediate posttest | 78 (54-92) | 80 (61-91) | 2.72 | 91 (82-95) | 84 (74-91) | 1.66 | — | — | — | ||
|
| 3 months postintervention | 84 (64-94) | 74 (55-87) | 5.47 | 92 (84-96) | 85 (75-91) | 1.84 | — | — | — | ||
|
| 6 months postintervention | 85 (64-94) | 92 (77-98) | 1.38 | 91 (82-95) | 92 (83-96) | 0.88 | — | — | — | ||
|
| ||||||||||||
|
| Baseline | — | — | — | — | — | — | 98 (94-99) | 98 (95-99) | — | ||
|
| Immediate posttest | — | — | — | — | — | — | 97 (92-77) | 98 (94-99) | 0.83 | ||
|
| 3 months postintervention | — | — | — | — | — | — | 98 (94-99) | 96 (92-98) | 2.43 | ||
|
| 6 months postintervention | — | — | — | — | — | — | 96 (91-98) | 96 (91-98) | 1.11 | ||
|
| ||||||||||||
|
| Baseline | — | — | — | — | — | — | 96 (92-98) | 91 (85-95) | — | ||
|
| Immediate posttest | — | — | — | — | — | — | 93 (87-96) | 91 (85-95) | 0.58 | ||
|
| 3 months postintervention | — | — | — | — | — | — | 93 (87-96) | 92 (85-95) | 0.40 | ||
|
| 6 months postintervention | — | — | — | — | — | — | 92 (86-96) | 92 (86-96) | 0.43 | ||
|
| ||||||||||||
|
| Baseline | 94 (90-97) | 92 (87-95) | — | 14 (9-20) | 15 (10-21) | — | 21 (16-28) | 34 (27-42) | — | ||
|
| Immediate posttest | 78 (71-84) | 73 (65-80) | 0.93 | 23 (16-31) | 28 (21-37) | 0.79 | 20 (14-27) | 20 (14-28) | 1.93 | ||
|
| 3 months postintervention | 72 (64-79) | 76 (67-82) | 0.58 | 22 (15-30) | 29 (22-38) | 0.75 | 15 (10-22) | 19 (14-27) | 1.46 | ||
|
| 6 months postintervention | 70 (61-77) | 66 (58-74) | 0.82 | 27 (20-35) | 26 (19-35) | 1.11 | 18 (12-25) | 18 (12-25) | 1.98 | ||
|
| ||||||||||||
|
| Baseline | 8 (5-13) | 13 (9-19) | — | 49 (40-59) | 46 (37-55) | — | 70 (63-77) | 61 (53-68) | — | ||
|
| Immediate posttest | 16 (11-22) | 18 (13-25) | 1.38 | 46 (37-56) | 45 (36-55) | 0.91 | 61 (53-69) | 58 (50-66) | 0.75 | ||
|
| 3 months postintervention | 17 (12-24) | 15 (10-22) | 1.90 | 47 (37-57) | 44 (35-54) | 0.97 | 68 (60-76) | 56 (48-64) | 1.11 | ||
|
| 6 months postintervention | 17 (12-24) | 20 (14-27) | 1.37 | 42 (33-52) | 43 (34-53) | 0.82 | 64 (55-72) | 55 (47-63) | 0.95 | ||
aMSM: men who have sex with men.
bM%, model-based mean probability of reporting behavior.
caOR: adjusted odds ratio (for intervention vs control change from baseline; regression models include independent variables of the intervention group [intervention, control], survey time point [baseline, immediate posttest, 3- and 6-month postintervention follow-up], and their interaction).
dSTI: sexually transmitted infection.
eNot applicable.
fP<.05.
gPrEP: preexposure prophylaxis.
hART: antiretroviral therapy.
iCondomless/PrEP-less anal sex for HIV-negative MSM and condomless/detectable viral load for HIV-positive MSM.
Figure 3HIV testing of high-risk GBMSM, reported by study time point and randomized allocation, in Atlanta, Detroit, and New York City (2018-2019). GBMSM: gay, bisexual, and other men who have sex with men.
Figure 4PrEP use among GBMSM who reported anal intercourse not protected by condoms or PrEP at baseline, reported by study time point and randomized allocation, in Atlanta, Detroit, and New York City (2018-2019). GBMSM: gay, bisexual, and other men who have sex with men; PrEP: preexposure prophylaxis.